Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 16/20 | 0.72 |
| ▸ | ADAM17 | P78536 | 15/20 | 0.72 |
| ▸ | MMP9 | P14780 | 6/20 | 0.72 |
| ▸ | MMP3 | P08254 | 2/20 | 0.72 |
| ▸ | MMP13 | P45452 | 4/20 | 0.68 |
| ▸ | MMP2 | P08253 | 4/20 | 0.57 |
| ▸ | MMP7 | P09237 | 3/20 | 0.56 |
| ▸ | MMP12 | P39900 | 3/20 | 0.56 |
| ▸ | MMP14 | P50281 | 3/20 | 0.56 |
| ▸ | MMP15 | P51511 | 3/20 | 0.56 |
| ▸ | MMP16 | P51512 | 3/20 | 0.56 |
| ▸ | MMP26 | Q9NRE1 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7111222 | 0.90 | MMP1 (0.66) | MMP1ADAM17MMP9MMP3MMP13 | |
| SCHEMBL5756389 | 0.90 | MMP1 (0.71) | MMP1ADAM17MMP9MMP3MMP13 | |
| SCHEMBL7105952 | 0.90 | MMP1 (0.71) | MMP1ADAM17MMP9MMP3MMP13 | |
| SCHEMBL5758586 | 0.85 | MMP1 (0.59) | MMP1ADAM17MMP9MMP3MMP13 | |
| SCHEMBL5759290 | 0.82 | ADAM17 (0.50) | MMP1ADAM17MMP9MMP3MMP13 | |
| SCHEMBL6382134 | 0.81 | ADAM17 (1.00) | MMP1ADAM17MMP9MMP3MMP13 | |
| SCHEMBL6237887 | 0.81 | ADAM17 (1.00) | MMP1ADAM17MMP9MMP3MMP13 | |
| SCHEMBL6236717 | 0.81 | MMP1 (0.70) | MMP1ADAM17MMP9MMP3MMP13 | |
| SCHEMBL7449575 | 0.81 | MMP1 (0.60) | MMP1ADAM17MMP9MMP3MMP13 | |
| SCHEMBL6235116 | 0.81 | ADAM17 (0.70) | MMP1ADAM17MMP9MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1104403-B1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | PFIZER PROD INC (US) | 2006-05-10 | — | — | EP | claimed |
| US-20030008901-A1 | Hydroxy pipecolate hydroxamic acid derivatives | MCCLURE KIM F (US) | 2003-01-09 | — | — | US | claimed |
| US-6329397-B1 | TREATMENT OF A CONDITION SELECTED FROM THE GROUP CONSISTING OF ARTHRITIS, CANCER, AND OTHER DISEASES CHARACTERIZED BY MATRIX METALLOPROTEINASE OR MAMMALIAN REPROLYSIN ACTIVITY. | PFIZER | 2001-12-11 | — | — | US | claimed |
| EP-1104403-A1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | claimed |
| WO-2000009485-A1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | claimed |
| EP-1104403-B1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | PFIZER PROD INC (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20030008901-A1 | Hydroxy pipecolate hydroxamic acid derivatives | MCCLURE KIM F (US) | 2003-01-09 | — | — | US | disclosed |
| US-6329397-B1 | TREATMENT OF A CONDITION SELECTED FROM THE GROUP CONSISTING OF ARTHRITIS, CANCER, AND OTHER DISEASES CHARACTERIZED BY MATRIX METALLOPROTEINASE OR MAMMALIAN REPROLYSIN ACTIVITY. | PFIZER | 2001-12-11 | — | — | US | disclosed |
| EP-1104403-A1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009485-A1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| EP-0960098-A1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES | PFIZER INC. (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998034918-A1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES | PFIZER INC. (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008901-A1 | Hydroxy pipecolate hydroxamic acid derivatives | MMP1, MMP10, MMP3 | MMP1 1/4885ADAM17 221/4885MMP9 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.